» Articles » PMID: 11313276

The Corepressor CtBP Interacts with Evi-1 to Repress Transforming Growth Factor Beta Signaling

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 2001 Apr 21
PMID 11313276
Citations 82
Authors
Affiliations
Soon will be listed here.
Abstract

Evi-1 is a zinc finger nuclear protein whose inappropriate expression leads to leukemic transformation of hematopoietic cells in mice and humans. This was previously shown to block the antiproliferative effect of transforming growth factor beta (TGF-beta). Evi-1 represses TGF-beta signaling by direct interaction with Smad3 through its first zinc finger motif. Here, it is demonstrated that Evi-1 represses Smad-induced transcription by recruiting C-terminal binding protein (CtBP) as a corepressor. Evi-1 associates with CtBP1 through one of the consensus binding motifs, and this association is required for efficient inhibition of TGF-beta signaling. A specific inhibitor for histone deacetylase (HDAc) alleviates Evi-1-mediated repression of TGF-beta signaling, suggesting that HDAc is involved in the transcriptional repression by Evi-1. This identifies a novel function of Evi-1 as a member of corepressor complexes and suggests that aberrant recruitment of corepressors is one of the mechanisms for Evi-1-induced leukemogenesis.

Citing Articles

Systematic pan-cancer analysis of the prognostic value of MECOM in human cancer.

Lu Y, Quan J, Liu F, Huang B Discov Oncol. 2024; 15(1):694.

PMID: 39576394 PMC: 11584820. DOI: 10.1007/s12672-024-01599-5.


Orthogonal proteogenomic analysis identifies the druggable PA2G4-MYC axis in 3q26 AML.

Marchesini M, Gherli A, Simoncini E, Moron Dalla Tor L, Montanaro A, Thongon N Nat Commun. 2024; 15(1):4739.

PMID: 38834613 PMC: 11150407. DOI: 10.1038/s41467-024-48953-3.


Oncogene drives acute myeloid leukemia via a targetable interaction with CTBP2.

Pastoors D, Havermans M, Mulet-Lazaro R, Brian D, Noort W, Grasel J Sci Adv. 2024; 10(20):eadk9076.

PMID: 38748792 PMC: 11095456. DOI: 10.1126/sciadv.adk9076.


TGF-β signaling in health, disease, and therapeutics.

Deng Z, Fan T, Xiao C, Tian H, Zheng Y, Li C Signal Transduct Target Ther. 2024; 9(1):61.

PMID: 38514615 PMC: 10958066. DOI: 10.1038/s41392-024-01764-w.


Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpression.

Birdwell C, Fiskus W, Kadia T, Mill C, Sasaki K, Daver N Leukemia. 2023; 38(3):545-556.

PMID: 38086946 DOI: 10.1038/s41375-023-02108-3.